---
title: "CareCloud Reaffirmed as a Top Healthcare IT Pick; Buy Rating and $8 Price Target Maintained on Strong Growth, Margin Upside, and AI-Driven Expansion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285813086.md"
description: "Analyst Allen Klee of Maxim Group has reaffirmed a Buy rating on CareCloud, maintaining a price target of $8.00. He cites strong operational momentum, double-digit revenue growth in 1Q26, and expectations for margin expansion. CareCloud's comprehensive product suite and AI-driven initiatives are expected to enhance productivity and customer acquisition. Klee highlights solid free cash flow and a favorable capital structure, supporting his positive outlook on the stock as a top healthcare IT pick for 2026."
datetime: "2026-05-09T12:25:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285813086.md)
  - [en](https://longbridge.com/en/news/285813086.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285813086.md)
---

# CareCloud Reaffirmed as a Top Healthcare IT Pick; Buy Rating and $8 Price Target Maintained on Strong Growth, Margin Upside, and AI-Driven Expansion

Analyst Allen Klee of Maxim Group reiterated a Buy rating on CareCloud, retaining the price target of $8.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Allen Klee has given his Buy rating due to a combination of factors that highlight both operational momentum and improving financial strength. He notes that CareCloud delivered double-digit revenue growth in 1Q26, beat his internal projections, and is entering the rest of 2026 with expectations for margin expansion as integration costs subside and seasonality reverses.

Klee also emphasizes that CareCloud now has its most comprehensive product suite ever, including a deeper push into inpatient software and an expanding AI layer that should boost productivity, margins, and customer wins. He points to solid free cash flow, a cleaner capital structure aided by the planned redemption of preferred stock, and a valuation discount versus peers, supporting his unchanged $8 price target and reinforcing his view of the shares as one of his preferred healthcare IT ideas for 2026.

According to TipRanks, Klee is an analyst with an average return of \-15.8% and a 29.46% success rate. Klee covers the Technology sector, focusing on stocks such as Roadzen Inc, Innodata, and Castellum.

### Related Stocks

- [CCLD.US](https://longbridge.com/en/quote/CCLD.US.md)
- [RDZN.US](https://longbridge.com/en/quote/RDZN.US.md)
- [INOD.US](https://longbridge.com/en/quote/INOD.US.md)
- [CTM.US](https://longbridge.com/en/quote/CTM.US.md)
- [CCLDO.US](https://longbridge.com/en/quote/CCLDO.US.md)
- [CCLDP.US](https://longbridge.com/en/quote/CCLDP.US.md)
- [RDZNW.US](https://longbridge.com/en/quote/RDZNW.US.md)

## Related News & Research

- [CareCloud begins to notify hundreds of thousands after hackers stole medical records](https://longbridge.com/en/news/294409693.md)
- [CareCloud amends 8-K to add Haq stock pledge agreements, 4,300,000-share warrant exhibits](https://longbridge.com/en/news/293797492.md)
- [14:26 ETICOHS College Expands AI Training Across Business and Healthcare](https://longbridge.com/en/news/293963968.md)
- [Elon Musk Just Revealed a Quiet Win for Tesla’s AI Ambitions](https://longbridge.com/en/news/293848955.md)
- [08:20 ETEbix Health Expands Medical Content and Coding Capabilities](https://longbridge.com/en/news/294206575.md)